New ways to give chemotherapy are changing the conversation for people with pancreatic tumors by sending medicine directly to the growth instead of flooding the whole body, and this piece follows a promising device-led approach, a patient’s turnaround, expert explanations of why local delivery matters, and early clinical trial signals that hint at better tolerance and survival.
Chemotherapy can save lives but its fallout is brutal for many patients, leaving them weak, nauseous and exhausted. Traditional IV chemo circulates through the bloodstream and damages healthy cells along with cancer cells, which is why targeted delivery is drawing attention. A system called Trans-Arterial Micro-Perfusion, or TAMP, aims to concentrate the drug right where it is needed.
An 83-year-old patient named Hernando found the difference firsthand after switching from standard treatment to the targeted approach at a cancer center. “The difference was tremendous,” Hernando said. “I completed eight sessions, one every 15 days, and I felt dramatically better than I did with the original chemotherapy.”
The platform uses a catheter-based device inserted into an artery near the tumor and is steered into place with imaging. “Once in position, two small balloons on the catheter are inflated, and the system is adjusted to isolate a targeted segment of artery adjacent to a tumor,” Bagai said. “The chemotherapy drug is then infused between the balloons, creating pressure to push the drug across the vessel wall and near the tumor, directly bathing the target tumor.”
That focused infusion is meant to push medicine across the vessel wall and into tumor tissue while reducing how much chemo reaches the rest of the body. “The procedure itself is minimally invasive and is typically performed in an outpatient setting without the need for patients to be put under general anesthesia,” Bagai said. For patients already battered by side effects, an outpatient option can feel a lot more manageable than repeated hospital stays.
Interventional oncologists say the physics of pancreatic tumors explain why this matters. “With IV chemotherapy, the drug travels through the bloodstream, affecting both cancerous and healthy cells, which can lead to side effects,” Dr. Gandhi said. He adds that many pancreatic tumors have few feeding vessels and a dense fibrous stroma that blocks drugs from reaching cancer cells efficiently.
To make the idea concrete, Dr. Gandhi used a simple image: “a drip irrigation system for individual plants instead of watering an entire lawn.” TAMP is designed so the drug is delivered near the tumor rather than depending on tumor feeder vessels to carry it from the bloodstream. “This targeted approach via TAMP does not rely on chemotherapy circulating through the body to carry the drug to the tumor via tumor feeder vessels,” Dr. Gandhi said. “Trans-arterial micro-perfusion is a drug-delivery platform that delivers chemotherapy directly near the target tumor where it is needed most.”
Early signals from the Phase III TIGeR-PaC trial are encouraging, though final results are still pending. “In the initial interim analysis of the TIGeR-PaC clinical trial, there was a trend towards improved overall survival by 6 months and improvement in the progression free survival by 8.1 months with 65% fewer adverse events in the TAMP arm of the study,” Dr. Gandhi said. If those trends hold, the approach could shift how some locally advanced pancreatic cancers are treated.
Not every patient is a candidate, and experts stress careful selection based on tumor stage, location and prior treatments. “He is precisely the type of patient who would benefit best from this approach because he has a tumor which is too far advanced to be treated surgically, but it has not spread to other organs,” Dr. Gandhi said. Clinical trials are also recommended when possible, with the panel noting that trials often give patients access to new options.
RenovoRx says the catheter platform is already cleared for general therapy use and is being studied specifically for intra-arterial gemcitabine in the TIGeR-PaC trial. “If positive, data generated from this trial could potentially support a new drug application for this combination product to the FDA for IAG,” Bagai said. The company believes the platform could be applied to other solid tumors with limited blood supply, not just pancreatic cancer.
For patients, the central promise is simple: fewer harsh systemic effects and more days that feel like normal life. Hernando noticed appetite and energy returning, and was even able to dance at a family wedding after treatment, a moment he described as priceless. Targeted drug delivery is not a cure-all, but for some people it could meaningfully change the balance between treatment and quality of life.
